This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Paul Claydon
Paul Claydon
Partner
London +44 20 7067 2060 pclaydon@cov.com Download V-card

Paul Claydon is a partner in Covington’s London office and is head of the firm’s corporate practice in Europe. He has more than 25 years’ experience in advising clients on mergers and acquisitions, IPOs and other securities issues, as well as corporate finance, private equity and venture capital transactions.

Mr. Claydon’s practice covers a wide range of industries; he has particular expertise in advising on deals in the life sciences and technology sectors. His clients include corporates, private equity funds and investment banks.

  • Axis-Shield plc, a diagnostics company listed on the London and Oslo stock exchanges, on the £235 million all cash public takeover by Alere, Inc., a U.S. company listed on the New York Stock Exchange. Alere’s offer for the company was initially made on a hostile basis and was defended by Axis-Shield and its advisors. Ultimately, the board of Axis-Shield recommended an increased cash offer from Alere valuing the company at £235 million.
  • Consort Medical plc, on its £230 million acquisition of Aesica Holdco Limited from Silverfleet Capital and its management and related £260 million equity and debt financing.
  • Cenkos Securities plc, as Sole Co-ordinator and Bookrunner on the £1.385 billion IPO on the London Stock Exchange main market of AA plc, the largest roadside assistance provider in the UK.
  • ReNeuron Group plc, a leading clinical stage stem cell therapy company on its £68.4 million follow-on financing by way of an institutional placing of new shares.
  • Horizon Discovery Group plc, a leading life sciences company that supplies research tools to organisations engaged in genomics research and the development of personalised medicines, on its IPO on the Alternative Investment Market of the London Stock Exchange and related £68.6 million fundraising. Also advising the Company on its subsequent £40.1 million follow-on financing by way of an accelerated bookbuild placing.
  • LMG Life Sciences Europe, Life Sciences Star - Financial & Transactional (United Kingdom) (2014-2015)
  • Chambers UK, Life Sciences (2013-2016)
  • Chambers UK, Life Sciences: Transactional (2012-2016)
  • Chambers UK, Capital Markets (2013-2016)
  • Chambers UK, Corporate/M&A: Mid-Market (2012-2016)
  • Chambers UK, Private Equity: Venture Capital Investment (2012-2014)
  • Chambers Global, Life Sciences (2014)
  • Super Lawyers - London, Corporate Finance (2013)
  • Best Lawyers in United Kingdom, Life Sciences and Venture Capital (2009-2014)
  • The International Who's Who of Life Sciences - Transactional Lawyers (2014)   
  • Legal 500 UK, M&A: Premium Deals (2012-2015)
  • Legal 500 UK, Flotations: Small & Mid-Cap (2011-2015)
  • Legal 500 UK, Media & Entertainment (2014-2015)
  • Legal 500 UK, Venture Capital (2011-2015)
  • Legal 500 UK, Pharmaceuticals & Biotechnology (2014-2015)
  • Legal 500 UK, Equity Capital Markets (2015)